Skip to content

You can have confidence in your biosimilar medicines

Learn more
Switching to biosimilars is safe and effective for patients
Learn more
Previous
Next

Who we are

Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.

About Biosimilars

As patents for original brand biologic medicines expire other manufacturers can produce new versions called biosimilars. Health Canada authorizes biosimilars for sale using the same rigorous regulatory standards as for all other biologic drugs, and there are no clinically meaningful differences in efficacy and safety between a biosimilar and the original brand biologic medicine.

Resources

Learn more about biosimilars and their benefits for patients and healthcare systems.

Latest news

Biosimilars, pharmacogenetics helping to shape the future of pharmacy benefits management

Benefits Canada report on the Face to Face Drug Plan Management Forum held on December 9, 2020.

Read more

How plan sponsors can contain rising drug costs in 2021

This Benefits Canada article highlights the importance of maximizing the use of biosimilar and generic medicines to ensure plan sustainability. 

Read more

IGBA Launches First Global Biosimilars Week

Biosimilars Canada is participating in this globally aligned educational initiative to raise awareness of biosimilar medicines from November 16 to 20.

Read more